signaling by Rho family GTPases has been addressed by several excellent reviews (e.g., Refs. 25, 26, 46, 103, 158, 193, 224, 230) . For in-depth coverage of signaling in smooth muscle, the reader is referred to more comprehensive reviews (e.g., Refs. 5, 66, 78, 86, 116, 150, 208, 216, 247) . A note on nomenclature used in this review, the term "Rho family proteins" will be used when we refer to Rho, Rac, and Cdc42 in general, whereas "Rho" or "Rho proteins" is reserved for RhoA proper. (73, 94, 104), is thought to be the key event in activating smooth muscle contraction in response to a wide spectrum of extracellular signals (216). Relaxation is induced by dephosphorylation of MLC 20 by a specific type 1 phosphatase, MLCP. MLCP is a heterotrimer consisting of a catalytic subunit, a 20-kDa subunit of unknown function, and a regulatory subunit, MYPT1, which targets MLCP to myosin (72, 97) (FIGURE 1). The degree of MLC 20 phosphorylation and, hence, smooth muscle tone is determined by the relative activities of these two opposing enzymes, whereby MLCP until the late 1980s was considered to be a constitutive active, unregulated enzyme (72). A series of publications brought Rho proteins and myosin phosphatase to center stage as regulators of smooth muscle function. First, there was the pivotal observation of A. P. and A. V. Somlyo and coworkers that G proteins increase Ca 2+ sensitivity of contraction and that this is due to inhibition of MLCP (112, 215). Inhibition of MLCP was later ascribed to phosphorylation of MYPT1 (90, 178, 232) . Second, the field was spurred by the seminal observation of Hirata and coworkers (79) that G-protein-induced Ca 2+ sensitization is due to activation of Rho mediating the inhibition of MLCP (164). Subsequent milestones were 1) the demonstration 342 1548-9213/09 8.00 ©2009 Int. Union Physiol. Sci./Am. Physiol. Soc.
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The small GTPases of the Rho family of monomeric GTPases, Rho, Rac, and Cdc42, emerged as master regulators of actin cytoskeleton remodeling and actomyosin-based contractility of smooth and non-muscle cells. Smooth muscle cells are major constituents of the walls of blood vessels and visceral organs (with the exception of the heart) and are responsible for dynamic changes in the diameter and volume of these hollow organs. Being a major player in the regulation of smooth muscle tone, Rho in conjunction with its effector Rho kinase, also known as ROK or ROCK, is essential for such diverse organ functions like regulation of arterial and pulmonary blood pressure, local organ blood flow, airway resistance, and passage of food through the gut to name a few. By regulating the contractile state of endothelial and epithelial cells lining the walls of blood vessels and visceral organs, Rho family proteins are also important determinants of their barrier function, which regulates the controlled transport of fluid and immune cells across the wall of these hollow organs.
Many of these functions involve not only myosin IIbased contractility but also the dynamic rearrangement of the actin cytoskeleton as well as regulation of gene expression. To fulfill these diverse functions, often several members of the Rho family with their specific regulatory proteins have to cooperate. In this scenario, individual members can be considered as nodal points in complex signaling networks that sort incoming environmental cues, distributing them to a subset of distinct intracellular signaling cascades to allow for the appropriate specific cellular answers. Not surprisingly, dysfunction of Rho signaling has been observed in such diverse pathologies like systemic and pulmonary hypertension, asthma, pulmonary fibrosis, erectile dysfunction, and vasospasms following subarachnoid hemorrhage.
The focus of this review will be on the regulation of smooth muscle tone by Rho and Rho kinase/ROK/ROCK in the following called ROK. We will touch the other GTPases when relevant within this context. As regards targets of Rho and ROK, we will concentrate on those directed toward the contractile machinery regulating its activity. The general aspects of that, like in non-muscle cells (184, 185) , Rho is activated by contractile agonists that signal through heterotrimeric G proteins (56, 62, 62, 95, 115, 171) , 2) the identification of ROK as Rho effector (3, 140) , and 3) the demonstration that ROK is responsible for the inhibitory phosphorylation of MYPT1 (50, 110). It was the availability of rather specific ROK inhibitors (223, 233) that in the years to follow overwhelmingly demonstrated the importance of Rho/ROK signaling in the regulation of contraction of every single smooth muscle under physiological and pathological conditions. Taken together, these findings provided a mechanistic explanation for the observation made already in the mid 1980s by Morgan and coworkers (147) who found that, in the presence of phenylephrine, [Ca 2+ ] i is more effective in maintaining force than it is in the presence of K + . Or in more general terms, stimulation of smooth muscle with agonists that activate G-protein-coupled receptors produces a force- [Ca 2+ ] i relation that is shifted to the left compared with K + -stimulated smooth muscle, a phenomenon now referred to as Ca 2+ sensitization (FIGURE 1) (106). Ca 2+ desensitization (FIGURE 1) in turn refers to the phenomenon that vasodilatation induced by cyclic nucleotides can occur without a concomitant decrease in [Ca 2+ ] i (146). It is now known that this is in part due to antagonizing Rho signaling.
By monitoring MLCK activation in intact smooth muscle tissue with a transgenic calmodulin biosensor mouse, the laboratory of Stull and Kamm (94, 144) recently demonstrated that Ca 2+ sensitization indeed can be ascribed to an increased sensitivity of force for MLCK activation. In other words, although carbachol and KCl induced the same increase in force and MLC 20 phosphorylation, carbachol treatment produced much smaller increases in Ca 2+ and MLCK activation, implicating inhibition of MLCP.
This overview of myosin-linked regulation of smooth muscle contraction would be incomplete without mentioning that actomyosin interaction is possibly regulated in addition in a MLC 20 phosphorylation-independent manner by the thin-filamentlinked proteins caldesmon and calponin (5, 109, 148, 175), a topic that will not be reviewed here.
Members of Small GTPases Involved in Smooth Muscle Contraction
The Ras (rat sarcoma) superfamily of monomeric GTPases consists of more than 100 members (21, 224, 244) , which are master regulators of many aspects of cell behavior (46). Based on their primary sequence and function, they fall into six subfamilies: Ras, Ran, Rad, Rab, Arf/Sar1, and finally Rho (244) . Rho family proteins emerged as key regulators of a variety of effects associated with changes in actin cytoskeleton, such as cell migration, adhesion, and contraction (Refs. 184, 186 ; reviewed in Refs. 25, 103). Still, h-Ras may play a role in smooth muscle function because it has been shown that h-Ras increases Ca 2+ sensitivity in permeabilized arteries (202) and regulates the expression of smooth muscle myosin light chain kinase (70).
Based on their effects on the actin organization, Rho family proteins are divided into five groups: the Rho-, Cdc42-, Rac-, Rnd-, and RhoBTB subfamilies (6, 25). Rho-, Rac-, and Cdc42-like proteins assume specific functions in the regulation of actin filament remodeling, such as formation of stress fibers, lamellipodia, and filopodial protrusions (25, 46, 103, 158, 162, 184) . Rnd proteins are endogenous negative regulators of Rho in smooth muscle (29, 129) . They are unique because they exist in a constitutively active GTP-bound form (53, 163) . Their expression level is high in the pregnant uterus but declines dramatically at the time of delivery, suggesting that Rnd proteins contribute to silencing of the uterus during pregnancy (27).
Identification of Rho Proteins as Key Regulators of Smooth Muscle Contraction
The involvement of Rho ] is increased either through activation of receptors coupled to heterotrimeric G proteins of the G␣ q/11 family and subsequent generation of inositol-trisphosphate or through influx through voltage-gated Ca 2+ channels (VGC). Activation of Rho and/or PKC signaling leads to an increase in Ca 2+ sensitivity due to inhibition of MLCP. Relaxation induced by cyclic nucleotides is either generated by receptors, coupled to the G s family of G proteins, or due to activation of guanylate cyclase by NO. These second messengers relax smooth muscle by 1) decreasing Ca
Rac and
The function of Rac and Cdc42 in differentiated smooth muscle is less well understood. Under certain conditions, Rac is antagonistic to Rho (Refs. 190, 197; reviewed in Ref. 25) . Rac is part of the NADPH oxidases NOX1 and NOX2, which play important roles in the development of vascular smooth muscle hypertrophy and migration (85, 135) as well as in endothelial barrier function (14, 113). The Rac effector PAK3 has been suggested to induce a Ca 2+ -and MLC 20 -phosphorylation-independent contraction by phosphorylating and disinhibiting the thin-filament-linked protein caldesmon (235) . In contrast, others found that PAK1 inhibits Ca 2+ -dependent activation of MLCK, thereby inhibiting contraction (152, 250) .
A novel interesting but still poorly understood concept suggests that the actin cytoskeleton is remodeled during agonist-induced contraction and that this remodeling process is important for tension generation in addition to the canonical actomyosin interaction (66, 109). Actin exists as monomers (G-actin) and filaments (F-actin). Coincident with activation of contraction, the proportion of F-actin at the cell cortex increases. This increased polymerization is orchestrated by Cdc42, which recruits WASp family proteins to the cell membrane resulting in activation of the Arp2/3 complex (227, 259) . Actin polymerization is also promoted by ROK-mediated activation of LIM kinase, leading to inactivation of the actin severing protein cofilin (138) (FIGURE 2B).
Of note, the increase in F-actin during stimulation of smooth muscle tissue is small (from ~80 to ~90%), and it is not clear at present how such a small increase is important for tension generation (109). One intriguing model suggests that the increase in F-actin at the cell cortex provides a rigid structure for force transmission to the extracellular matrix and between smooth muscle cells (66). Tight coupling between smooth muscle cells is obviously necessary for effectively altering the diameter of hollow organs.
Regulation of the Activity of Rho, GEFs, GAPs, and GDIs Like all small GTPases, Rho proteins are molecular switches that cycle between a GDP-bound "off" and a GTP-bound "on" state (22). The "on" fraction of Rho depends on the concerted action of three classes of regulators (FIGURE 2A), namely guanine nucleotide exchange factors GEFs (21, 132, 191, 207) , GTPase activating proteins GAPs (11, 21, 145, 206) , and GDP dissociation inhibitors GDIs (37 -sensitization induced by GTP␥S and contractile  agonists in permeabilized smooth muscle (62, 79, 95, 164, 171, 226) . We note that these toxins are not entirely specific for RhoA; EDIN and C3 inactivate RhoA, B, and C by mono-ADP-ribosolating them at Asn41 (236) , whereas toxin B inhibits Rho, Rac, and Cdc42 by glucosylating Rho at Thr37, and Rac and Cdc42 at the homologous amino acid Thr35 (98, 211). Since the inhibitory effect of EDIN and C3 was rescued by recombinant RhoA proteins, inhibition of Ca 2+ sensitization can be ascribed to inhibition of RhoA (79, 171). Second, incubation of permeabilized smooth muscle with recombinant RhoA proteins increased Ca 2+ sensitivity, albeit at a slower rate and with a smaller amplitude compared with agonist-or GTP␥S-induced Ca 2+ -sensitization (61, 62, 79, 129). In addition, treatment of the permeabilized smooth muscle with recombinant RhoA-augmented agonist induced Ca 2+ sensitization and delayed its rundown (171) . Third, in intact smooth muscle, membrane-permeable toxins inhibited the tonic but not the initial phase of contractions elicited by muscarinic and adrenergic agonists, demonstrating that it is the late phase of a contraction that is Rho dependent (55, 134, 171). These findings indicate that Rho proteins are both necessary and sufficient to increase Ca 2+ sensitivity under these experimental conditions. However, we also note that whether and to what extent Ca 2+ sensitization is inhibited by the bacterial toxins depends on the agonist, on the tissue, and perhaps also on the species indicating that other pathways can lead to Ca 2+ sensitization as well (e.g., Refs. 62, 200, 226; reviewed in Ref. 176) .
Interestingly, Rho/ROK not only regulates Ca 2+ sensitivity but also expression of smooth muscle differentiation genes that define the contractile phenotype of smooth muscle (172, 239) . These genes include smooth muscle ␣-actin, smooth muscle myosin heavy chain, and calponin, i.e., proteins of the contractile machinery. In the so-called synthetic phenotype, which predominates during development and after injury expression of these genes, is downregulated (172, 254) . Transcription of the contractile proteins is activated by serum response factor (SRF) and is dependent on RhoA, whereby the effect of RhoA may be secondary to Rho-mediated increase in actin polymerization (76, 136, 238) . In keeping with these ideas, maintenance of smooth muscle phenotype of blood vessels in organ culture depends on activation of Rho and actin polymerization and appears to critically require mechanical loading by stretching them (2) . It is therefore tempting to speculate that Rho is a nodal point that orchestrates downstream effectors that regulate the short-term mechanical output of smooth muscle coincident with the long-term maintenance of their contractile phenotype (239) . interaction, posttranslational modification, and second messengers (11, 21 RhoA-GDI complex and extracts Rho from the cell membrane (179 (220) , whereby p190GAP appears to be the most important one (23, 149). Inhibition of GAP activity is sufficient to induce activation of Rho in the absence of extracellular stimuli, demonstrating that GAPs are necessary to maintain Rho/ROK activity low under basal conditions (11, 23). Furthermore, it was reported recently that angiotensin II (23) and endothelin (149) can increase GTP-loaded Rho by decreasing p190GAP activity.
Some GAPs are bifunctional because they contain a GEF domain for another GTPase. In this way, one GTPase can be turned off coincident with turning on the other. Since different Rho GTPases control and orchestrate distinct subsets of downstream signals; such a mechanism allows for a coordinated switch from one functional cellular state to another, e.g., from a Rho-controlled contractile (225, 253) to a Rac-controlled migratory and proliferating state (19).
GDIs forming 1:1 complexes with Rho maintain the hydrophobic Rho as a soluble cytosolic protein by shielding the COOH terminal geranylgeranyl membrane-targeting moiety (Ref. 170 ; reviewed in Ref. 37). GDIs prevent the GDP/GTP exchange and the interaction of Rho-GTP with GAPs or its effectors (37). Recombinant GDI inhibited phenylephrine-and carbachol-induced Ca 2+ sensitization in permeabilized portal vein and ileal smooth muscle (61). Since translocation of Rho to the cell membrane is a prerequisite for activation by GEFs, mechanisms must exist that coordinate GDI dissociation from Rho with activation of GEFs. Unfortunately, the regulation of the interaction of Rho with GDI in smooth muscle is largely undefined. One possible intriguing mechanism involves phosphorylation of GDI. For instance, phosphorylation at Ser96 by PKC in endothelial cells lowers the affinity of GDI for Rho (141). We note that most agonists activate PKC via G␣ q and RhoGEFs via G␣ 12/13 , allowing for coordination of the amount of available free RhoA and GEF activation by this mechanism, a hypothesis that needs experimental confirmation.
Interestingly, phosphorylation of GDI at a different site, namely Ser174 by PKA, enhances formation of the Since activation of Rho by high K + is absolutely dependent on Ca 2+ (196) , it may be the KCl-induced increase in cytosolic [Ca 2+ ] rather than the membrane depolarization per se that activates Rho. Possible mechanisms of Ca 2+ -induced activation of Rho include class II PI3 kinases (240, 258) . Alternatively, Ca 2+ may activate sphingosine kinase leading to release of sphingosine-1-phosphate and paracrine activation of S1P receptors (242) .
Coupling of heterotrimeric G proteins of the G␣ ␣ 12 and G␣ ␣ q family to Rho activation
Activation of Rho has been demonstrated in different types of smooth muscle in response to a large number of contractile agonists (125, 127, 195, 216) . With few exceptions, most of these agonists activate through their specific G-protein-coupled receptors (GPCRs) more than one G protein of the G␣ q , G␣ 12 , or G␣ i family (FIGURE 2B) (60, 188). Examples include the endothelin ET A , the ␣ 1 -adrenoceptor, the muscarinic M 1 and M 3 , the 5-HT 2C , the angiotensin AT 1 , lysophosphatidic acid LPA, and the sphingosine-1-phosphate S1P 2 and S1P 3 receptors, which activate both G␣ q/11 and G␣ 12/13 (see tables in Refs. 139, 150, 246). Hence, on the one hand, a limited number of G proteins integrates the information from a large number of environmental stimuli and distributes it to distinct intracellular signaling cascades. On the other hand, a high level of complexity exists. This is because there is extensive crosstalk between these signaling cascades including feed-forward and feedback regulation.
Of the different pathways that mediate GPCRinduced activation of Rho, signaling through G␣ 12/13 is best understood. Thus activated G␣ 12/13 binds the RGS-like domain containing Rho-GEFs, PDZ-RhoGEF, LARG, and p115 RhoGEF (for reviews, see Refs. 188, 193, 216) , thereby positively regulating their Rho-GEF activity, resulting in activation of Rho (Refs. 57, 71; reviewed in Ref. 58). At the same time, these GEFs switch off the upstream signal. This is because their RGS-like domain acts as a GAP for G␣ 12/13 (Ref. 118; for review, see Ref. 58). It was proposed that this mechanism limits activation of Rho to rapid and robust activation of G␣ 12/13 , which is thought to increase the signal-to-noise ratio (191) . As will be detailed below, these GEFs can also be activated by tyrosine phosphorylation (e.g., Ref. 31).
Although it was shown that expression of constitutive active G␣ 12/13 contracts VSMC in a Rho-dependent manner (60), mice deficient for G␣ 12/13 or LARG had a normal basal blood pressure (249) . Interestingly, development of salt-sensitive hypertension was abrogated in both the G␣ 12/13 and LARG-deficient mice. -independent myosin light chain kinases, ROK, integrin linked kinase (ILK), p21-activated kinase (PAK), and ZIP kinase. MLCK in turn is inhibited by protein kinase A (PKA) and PAK1, the latter being activated by the small GTPase Rac. Myosin phosphatase consists of three subunits: the regulatory subunit MYPT1, the catalytic subunit PP1c, and a 20-kDa subunit of unknown function (M20). MYPT1 is phosphorylated at different threonines by several kinases, which as net effect decreases its activity. PKA and PKG phosphorylate MYPT1 at S695, which has no effect on its activity but blocks subsequent phosphorylation at T696. MLCP activity is enhanced by telokin, in particular when telokin is phosphorylated by PKA/PKG (255) . The activity of MLCP is decreased by the phosphopeptide CPI-17. http://physiologyonline.physiology.org/ G␣ q signaling blocked ROK activation (81, 87, 217, 260) . Little is known in smooth muscle about the mechanisms that functionally link G␣ q to Rho activation. In model cell systems, it may occur through specific RhoGEFs like LARG (20, 32, 237) and/or tyrosine phosphorylation (31, 107). However, it is not clear whether G␣ q is sufficient to induce Rho activation (32, 43, 107, 192) or whether signal transmission requires additional factors (9, 225). Since in smooth muscle activation of G␣ q leads to an IP 3 -mediated increase in intracellular [Ca 2+ ], it is possible that membrane depolarization and activation of G␣ q converge on Ca 2+ with subsequent activation of Rho through the above-described mechanisms.
G␣ ␣ q and G␣ ␣ 12/13 activate Rho through nonreceptor tyrosine kinases (non-RTK)
Involvement of non-RTK in GPCR-induced contraction were first implicated by the finding that different inhibitors of non-RTK prevented Ca 2+ sensitization elicited by adrenergic and muscarinic agonists (40, 199, 219) . There is now compelling evidence that GPCRs and certain lipids can activate Rho/ROK signaling through activation of non-RTKs in smooth muscle (114, 157, 195, 199) (FIGURE 2B). Non-RTKs have been shown to phosphorylate LARG and PDZRhoGEF, which enhances their GEF activity toward Rho (31, 168, 222) . In addition, in fibroblasts, cSrc phosphorylated RhoGDI at residue Tyr156. This decreased the ability of RhoGDI to form a complex with RhoA (38). Since non-RTK can be activated downstream of Rho by ROK, they may be a component in a positive feedback loop (31) prolonging the "ontime" of these Rho-GEFs and increasing available free RhoA (38, 216).
Downstream Targets of RhoA: Rho Kinase as a Master Regulator of Smooth Muscle Contraction
Of the Rho effectors shown in FIGURE 2B, ROK is one of the best characterized ones and is the most important one for regulation of smooth muscle contraction (130). Two isoforms of ROK have been identified, ROK␣ (also known as ROCK-2) and ROK␤ (also known as ROCK-1) (130, 187). Both isoforms are expressed in smooth muscle, possibly serving distinct functions (241) . ROKs are serine/threonine kinases, which have a NH 2 -terminal catalytic domain, a central coiled-coil domain and a COOH-terminal PH and RB domain. Binding of Rho-GTP to the RB-domain causes a derepression and a so-called "open" conformation of the kinase, whereby the activity increases approximately twofold. Such an open conformation likely is also induced in a Rho-independent manner by certain lipids such as arachidonic acid (4, 130 development of hypertension but not for the regulation of blood pressure under basal conditions, a conclusion supported by earlier experiments with ROK inhibitors (233) . This finding may not be surprising because the contractile response to stimulation with the ␣-adrenergic agonist phenylephrine was not affected in aortas isolated from the knockout mice. In contrast, the contractile response to endothelin, U46619, and angiotensin II was attenuated, albeit to different extents (249) . This is consistent with earlier observations that these agonists differ in their ability to increase the amount of GTP-bound Rho (195) and to induce Ca 2+ sensitization (77).
Since the contractile response to phenylephrine and serotonin was completely abrogated in G␣ q -deficient mice, these agonists, unlike the other ones, appear to couple exclusively through G␣ q (249) . Still, both agonists increase Ca 2+ sensitivity of smooth muscle contraction (62, 201), and several lines of evidence suggest that this may be due to G␣ q -mediated activation of Rho. First, these agonists increase active Rho in vascular smooth muscle (195) and in G␣ 12/13 -deficient fibroblasts (237) . Second, interventions that interfered with REVIEWS FIGURE 4. Putative mechanisms by which cyclic nucleotides antagonize Rho activation
The canonical pathway of cAMP leads to activation of PKA, which, like PKG, can phosphorylate GDI as well as Rho. Phosphorylation of Rho and/or GDI enhances the affinity of GDI for Rho-GTP and sequesters Rho-GTP into the cytosol. In addition, PKG can block signal transduction from G␣ 12/13 to Rho. A still putative novel pathway, deduced from non-muscle cells, suggests that cAMP also activates exchange factors directly activated by cAMP (EPACs), which in turn activates the small GTPase Rap1. Rap1 activates a GAP for Rho (e.g., Arap3), thereby promoting the inactivation of Rho and binding to GDI. sensitivity permeabilized smooth muscle (4, 54) and is raised in response to certain contractile agonists (62, 67). Another lipid, sphingosylphosphorylcholine (SPC) has also been suggested to directly activate ROK (214) and is likely responsible for long-term vasospasms of cerebral arteries following subarachnoid hemorrhage (122).
ROK phosphorylates several targets at the contractile machinery (FIGURE 2B). The most important effect of ROK is the inhibition of MLCP activity (see below), which leads to an increase in MLC 20 phosphorylation. In addition, ROK phosphorylates MLC 20 directly (121); however, this appears to be of minor importance in smooth muscle. ROK phosphorylates calponin (105), and this may account for the MLC 20 phosphorylation-independent force enhancement (137). Further targets include LIM kinase, which phosphorylates cofilin, leading to inhibition of its actin filament severing function (138). Thus the overall effect is to enhance actomyosin interaction and to prevent actin depolymerization.
Much of the current understanding of ROK as a key regulator of smooth muscle contraction is based on pharmacological tools, i.e., the ROK inhibitors Y-27632 (93, 233) and H1077, also called fasudil (154). These compounds have been shown to inhibit force in vascular (16, 156, 233) , respiratory (30, 92), ileal (178, 223) , bladder (99, 229), myometrial (120), and gastric fundus (183) smooth muscle. They are considered to be rather specific because their K i values of 0.14 M (Y-27632) and 0.33 M (HA1077) are much lower than those for PKA, PKC␣, and MLCK (233) . Furthermore, of a large panel of kinases tested by Cohen and coworkers (7, 34), only two other kinases were inhibited by Y-27632 with similar potency as ROK. These kinases are PRK1 and 2, also called PKN1 and 2, distinct Rho-dependent kinases that phosphorylate CPI-17 (see below and Ref. 69). Since Y-27632 inhibits ROK by competing for ATP (93), it is not surprising that the IC 50 value for inhibiting vascular smooth muscle contraction is higher (~1 M) with maximal inhibition at 10 M (233). However, when drawing conclusions about involvement of ROK, one should be aware that, at 10 M, Y-27632 also inhibits PKC␦ in vascular smooth muscle (47, 151). Hence, even though the ROK inhibitors have a much better specificity compared with other inhibitors of serine/threonine kinases (7), firm proof of the involvement of ROK requires supplementation by, e.g., molecular analysis (174).
Myosin Phosphatase as Target of ROK
ROK inhibits MLCP primarily by phosphorylation of its regulatory subunit, MYPT1 (97) (cf. FIGURE 3) . MYPT1 is phosphorylated at several serine and threonine residues by a number of kinases, including ROK and ZIP kinase, whereby Thr696 and Thr853 seem to be the major phosphorylation sites for ROK (97) (FIGURE 3). More recently, it was proposed that ROK indirectly phosphorylates Thr696 by activating ZIP kinase (68). Phosphorylation of Thr696 inhibits enzymatic activity, whereas phosphorylation of Thr853 lowers the affinity for its substrate myosin, resulting in an apparent decrease in MLCP activity (97). In smooth muscle, both sites are significantly phosphorylated already under resting conditions in a ROK-independent manner (e.g., Refs. 111, 133, 160). Although most investigators found that phosphorylation of Thr853 increases in response to contractile agonists in a ROKsensitive manner, the correlation between increase in force and Thr696 phosphorylation is much more variable (96, 101, 111, 133, 144, 248 ). MYPT1 is also phosphorylated by PKA/PKG at Ser695, which has no effect on MLCP activity (FIGURE 3) but prevents subsequent phosphorylation of Thr696, thereby possibly regulating the availability of MYPT1 for ROK-mediated inhibitory phosphorylation (155, 159, 217, 252) .
Under certain conditions (e.g., Ref. 174), ROK inhibits MLCP also by phosphorylating the endogenous inhibitory peptide of MLCP, called CPI-17 (FIGURE 3). CPI-17 is predominantly expressed in vascular smooth muscle and was initially discovered as a protein kinase C (PKC) substrate (48). It is now known that CPI-17 can be phosphorylated in vitro by a number of kinases including ROK (117), PKN (69), and integrin-linked kinase (35); however, in smooth muscle, phosphorylation by PKC appears to predominate (47).
Temporal and Spatial Aspects of Ca

2+ -and Rho-Signaling
As already mentioned, most contractile agonists activate both G␣ q and G␣ 12/13 . The canonical downstream events initiated by G␣ q signaling are generation of IP 3 and diacylglycerol followed by release of intracellular Ca 2+ and activation of PKC, respectively, whereas G␣ 12/13 activates Rho. In this way, signaling events that lead to activation of the Ca 2+ /CaM-dependent MLCK and those that lead to inhibition of MLCP are activated in parallel, however, possibly with different kinetics. In the tonic vascular smooth muscle, the increase in [Ca 2+ ] is typically rapid followed by a decline to lower but still suprabasal levels, whereas force is maintained (e.g., Refs. 41, 147, 161). In other words, force is sensitized to the activator Ca 2+ . The activation of MLCK follows this Ca 2+ transient (94), whereas activation of Rho/ROK is thought to occur slower than the rate of tension rise and is sustained (41, 143, 223 ). This sustained activation of Rho, which predominantly occurs at the cell membrane where Rho meets its effector, ROK (61, 143), is considered to be responsible for the sustained increase in MLC 20 phosphorylation and Ca 2+ sensitization (143).
The notion that activation of Rho/ROK occurs at a slow rate was deduced from the findings that does not necessarily rise in parallel. Thus, in arterial smooth muscle, only CPI-17 is phosphorylated during the rising phase of the contraction, whereas, during the sustained phase, both proteins are phosphorylated (41). In contrast, in the phasic bladder smooth muscle, the initial phase of the carbachol-induced contraction was associated with a PKC-dependent phosphorylation of CPI-17 as well as a PKC-and/or ROK-dependent phosphorylation of MYPT1, whereas during the later phase only MYPT1 phosphorylation persisted (144). Furthermore, CPI-17 phosphorylation occurred at lower carbachol concentrations than MYPT1 phosphorylation (144).
PKC and Rho signaling cascades not only represent two parallel pathways, they also interact. For instance, Rho activates PLD (49), which results in a prolonged activation of PKC (151), whereas vice versa PKC can activate Rho by a not yet defined mechanism (8, 173). Furthermore, it was suggested that, in intestinal smooth muscle, PKC indirectly phosphorylates MYPT1 at the ROK sites by activation of integrinlinked kinase ILK (91), whereas in turn, in vascular and bronchial smooth muscle, ROK can phosphorylate the PKC substrate CPI-17 (160, 174, 194) .
To conclude, whether PKC and Rho/ROK cooperate or act individually to increase Ca 2+ sensitivity depends on the type of smooth muscle (200, 226) , partly because the expression level of CPI-17 differs between tonic and phasic smooth muscle (251) . It also depends on the time in the course of a contraction (41, 144, 161), the applied agonist (74, 200, 260) , the concentration of a given agonist (144), and for a given mode of stimulation on the species (42, 200).
PKA/PKG decrease Ca 2+ Sensitivity Through Inhibition of Rho Signaling
It has been known for more than 20 years that cyclic nucleotides relax smooth muscle by decreasing Ca 2+ sensitivity (146), whereby the underlying mechanisms are still not fully understood. The initial proposal that cAMP decreases MLCK activity was later questioned (116). Both cAMP and cGMP converge on MLCP to increase or rather disinhibit its activity (124, 133, 155) both in a Rho-independent manner (88, 108, 221, 252, 255) and/or by antagonizing Rho/ROK signaling (18, 153, 159, 203) .
Antagonizing the Rho pathway can occur at several steps along the pathway from G␣ 12/13 to Rho itself (FIGURE 4). As described in the chapter "Regulation of the Rho activity, " an attractive mechanism to inactivate Rho in vascular smooth muscle cells is the PKG-mediated phosphorylation of Rho resulting in an increased Rho-GDI complex formation and extraction of Rho from the plasma membrane (203) . However, the NOmediated inactivation of Rho in hamster microarteries was not blunted by overexpression of a non-phosphorylatable mutant of RhoA, RhoA Ser188Ala (18).
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PHYSIOLOGY • Volume 24 • December 2009 • www.physiologyonline.org maintained force rather than the initial rise in tension was inhibited by chimeric DC3B toxin (55) or Clostridium difficile toxin B (134) or by the ROK inhibitors Y-27632 and fasudil (223) . Several observations challenge this view. First, ROK inhibitors inhibit rhythmic contractions of rat ureter smooth muscle induced by electrical field stimulation (212) . Second, Clostridium difficile toxin B inhibited the initial rise in MLC 20 phosphorylation in ileal smooth muscle, interestingly without significant inhibition of force (134). Third, direct determinations of MLCK activation in the phasic bladder smooth muscle indicated that inhibition of MLCP significantly contributes to the carbachol-induced rise in force (144).
Despite this, a large body of evidence suggests that the early phase of the increase in MLC 20 phosphorylation is governed by activation of MLCK, whereas activation of Rho/ROK governs the late phase. The lifetime of the "on" state of Rho, i.e., the rate of GTP hydrolysis, will determine the duration and amplification of downstream signal propagation (22). As mentioned, the intrinsic GTPase activity of Rho is significantly accelerated by GAPs. Nevertheless, little is known about the regulation of kinetics of inactivation of Rho in smooth muscle, which is of great biological importance. For instance, since Rho/ROK signaling is not only involved in the tonic contraction of blood vessels as already mentioned but also in the phasic contractions of uretral smooth muscle (212) , it will be interesting to see whether the lifetime of GTP-loaded Rho differs between these different types of smooth muscles. Furthermore, augmented Rho signaling has been implicated in several vascular diseases such as hypertension and vasospasms of cerebral arteries (209) . One possible mechanism might involve increasing the lifetime of GTP-loaded Rho by downregulation of GAP activity (149).
There is also some evidence for spatial regulation of Rho signaling. For instance, the initial, MLCK-dependent MLC 20 phosphorylation occurs at the central region, whereas the sustained, Rho-dependent MLC 20 phosphorylation occurs at the cell cortex (143). In addition, MYPT1 is translocated from the cytosol to the cell membrane during stimulation of smooth muscle (17, 159, 213); however, the functional relevance has yet to be determined.
Different Roads Lead to Ca
2+
Sensitization: Cross Talk Between PKC and Rho/ROK Signaling Unfortunately, phosphorylation of GDI was not investigated in this study. Hence, the mechanism of inactivation of Rho by PKG/PKA is still not fully understood.
Recently, it was demonstrated in endothelial cells that cAMP may enhance barrier function independent of PKA by activating so-called EPACs, exchange proteins activated by cAMP (14) (FIGURE 4). EPACs are GEFs for Rap1 (84). Of its downstream effectors, RhoGAPs are particularly interesting because they decrease the activity of Rho. Preliminary experiments indicated that cAMP analogs, which rather specifically activate EPACs (84), resulted in a decrease in Ca 2+ sensitivity of contraction (177) . Whether this is due to Rap1-mediated activation of the RhoA-GAP ARAP3 (as demonstrated in Refs. 119, 218) remains to be seen.
Potential Role of Rho/ROK Dysfunction Causing Disease
Since the initial report that inhibition of ROK lowers blood pressure in different animal models of hypertension (233) , an ever increasing number of reports described dysregulation of Rho Here, we just want to emphasize one aspect, namely that most of these pathologies cannot be simply ascribed to altered smooth muscle function. Rather they involve a complex interaction between smooth muscle cells, the endothelial/epithelial lining, activated platelets, and mast cells within the walls of the visceral organs or blood vessels (e.g., Ref. 24; reviewed in Refs. 209, 242) . For instance, diseases like hypertension and diabetes are associated with endothelial dysfunction and a decrease in NO bioavailability. This likely leads to a shift from the rapidly activatable cytosolic GDI-Rho-GTP complex to the active membranebound Rho (131). At the same time, the increased Rho/ROK activity causes a decreased endothelial eNOS expression (Ref. 15; for review, see Ref. 33) and mRNA stability (100, 123), thus creating a viscous cycle. Furthermore, by antagonizing Rho signaling, PKA not only ameliorates pulmonary hypertension (89) but also has a protective effect against pulmonary barrier dysfunction seen under many inflammatory conditions (180) . Hence, the beneficial effects of Rho/ROK inhibitors are likely not simply due to normalization of smooth muscle tone but also involve inhibition of proliferation and cell migration, i.e., reversing the remodeling processes (for reviews, see Refs. 169, 181, 209) .
Concluding Remarks
The mechanical output of smooth muscle and also non-muscle cells is the summation of these stimulatory and relaxing signals, which are integrated at the level of the contractile machinery mainly through MLCP. This also means that it is misleading to investigate these signals in a linear way, often necessary to reduce complexity for the time being, without taking into consideration that a highly complex network of signaling cascades regulates the contractile machinery. These pathways exhibit properties of positive and negative feedback and interact extensively at the level of the GTPases (25) but also further downstream. Despite the fact that the major pathways have been outlined, there are still significant gaps in our knowledge. For example, information is limited regarding the regulation of Rho activity and its cross talk with other GTPases in differentiated smooth muscle.
The mechanical output of smooth muscle itself is rather complex, exhibiting widely different contractile patterns with graded responses and different temporal profiles to environmental stimuli. Such a complex mechanical pattern requires signaling modules that can encode both the signal intensity and also the duration of the environmental signal (10). We still do not fully understand how the different modules are put together to obtain a specific contractile response both in amplitude and duration. It also appears likely that some of these modules can be exchanged for each other without affecting the overall effect, e.g., Ca 2+ sensitization not always relies on Rho/ROK (e.g., Refs. 42, 200) . Given the fact that Rho and ROK regulate a vast number of cell functions in addition to regulation of smooth muscle tone acting over different time scales (102), understanding the precise temporal and spatial aspects of signaling to the contractile machinery should possibly lead to better-tailored therapeutic strategies.  Because of space limitations, the reference list is by no means comprehensive and we do apologize to the many authors who significantly contributed to our understanding of Rho signaling and whose work is not cited here. We thank R. Stehle for stimulating discussions and D. Metzler for the artwork. The helpful comments of the anonymous reviewers are gratefully acknowledged.
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